Boron One Announces Closing of Financing
VICTORIA, BC / / June 19, 2025 / Boron One Holdings Inc. ("Boron One" or the "Company") [TSXV:BONE]") is pleased to announce that the Company has accepted subscriptions for 4,120,000 units at a price of $0.05 per unit, for gross proceeds of $206,000. Each unit is comprised of one common share and one common share purchase warrant, exercisable at $0.05 for one year, and $0.07 for 2 further years.
The Common Shares and Warrants comprising the Units will be subject to a four-month and one day hold period in accordance with the policies of the TSX Venture Exchange and applicable securities legislation.
The Company intends to use net proceeds of the Private Placement for working capital requirements.
The Private Placement is subject to certain conditions including, but not limited to, the receipt of all necessary approvals, including approval from the TSX Venture Exchange.
On behalf of the Board of Directors,Tim Daniels, President
About Boron One Holdings Inc.
Boron One Holdings Inc. is an international mineral exploration and development company with boron assets in Serbia. Headquartered in Victoria, B.C., Canada, Boron One's shares are traded on the TSX Venture Exchange under the symbol "BONE". For detailed information please see Boron One's website at www.boronone.com or the Company's filed documents at www.sedar.com.
For further information, please contact:Boron One Holdings Inc.Blake Fallis, General ManagerPhone: 1-250- 384-1999 or 1-888-289-3746info@boronone.comwww.boronone.com
Boron's Public Quotations:CanadaTSX Venture: BONEBerlin: EKVUS: SEC 12G3-2(B) #82-4432ERVFFOTCBB: ERVFF
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
SOURCE: Boron One Holdings Inc.
View the original press release on ACCESS Newswire
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Forbes
an hour ago
- Forbes
The 2nm Race: Intel's 18A Faces Uphill Task Against TSMC
CANADA - 2025/05/26: In this photo illustration, the Intel Corporation logo is seen displayed on a ... More smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images) Intel (NASDAQ:INTC) has been fully committed to transforming itself into a global foundry leader, especially as the competition for next-generation 2-nanometer (nm) chips intensifies with its 18A process at the heart of its strategy. Over the last four years, the company has poured more than $90 billion into capital expenditures aimed at expanding its foundry operations and narrowing the gap with TSMC and Samsung. The stakes are considerable. The foundry segment suffered losses of nearly $13 billion last year, and Intel's shares have decreased by nearly 50% since their peak in 2024. So, how does Intel's new technology compare with that of its rivals? In the realm of chip manufacturing, 'nm' indicates the size of the process node in nanometers. Generally, smaller nodes allow for an increased number of transistors to be integrated into a designated area, leading to enhanced performance, improved energy efficiency, and the ability to accommodate more intricate designs. This is particularly crucial for high-performance applications such as AI, smartphones, and advanced server tasks. However, transitioning to smaller nodes is a costly and complicated endeavor. Initial yield rates are often lower, and the investment required to construct and equip fabrication facilities for such advanced production is substantial. Intel is optimistic that its new 18A process, which employs 1.8nm technology, is presently in risk production. Here, initial batches are utilized to evaluate and enhance the manufacturing process before mass production begins. Laptops utilizing 18A-based processors are already being sampled with original equipment manufacturers (OEMs). This process creates chips employing technologies like RibbonFET gate-all-around transistors and PowerVia backside power delivery. These innovations permit the creation of smaller transistors that enhance performance and energy efficiency. PowerVia could provide significant benefits for AI applications as well as high-performance computing tasks. The rollout of Intel's 18A is occurring just as its competitors are gaining momentum. TSMC, the leading player in the foundry market, commands over two-thirds of the overall foundry space and is expected to retain its lead in the 2nm generation by a considerable margin. TSMC plans to commence mass production of its 2nm process in the latter half of 2025 at its fabrication facilities in Taiwan. TSMC's 2nm process represents its first incorporation of gate-all-around (GAA) transistor architecture, which promises a 10% to 15% enhancement in performance and up to 30% reduction in power usage in comparison to its 3nm node. Furthermore, TSMC has demonstrated exceptional manufacturing prowess. As reported by the Taiwan Economic Daily, current yields for the 2nm process are at 60%, indicating that out of every 100 dies sliced from a silicon wafer, 60 meet quality control standards. That's a remarkable statistic. Some reports from March estimated that Intel was only achieving yields of between 20% to 30% on its 18A process, while Samsung was reportedly achieving 40% yields on its rivaling technology. TSMC's customer base is also extensive and loyal, featuring major clients like Apple and AMD that have already committed to utilizing its 2nm process. Even Intel is diversifying its strategy, engaging TSMC as an alternative source for some of its forthcoming Nova Lake desktop processors, anticipated in 2026. Counterpoint Research projects that TSMC may achieve full utilization of its 2nm capacity by the fourth quarter of 2025. Now, Intel asserts that the 18A process will provide improved performance and reduced power usage compared to TSMC's competing node. Nonetheless, TSMC's chips are likely to maintain an edge in terms of density and cost. Compounding Intel's difficulties, the company has experienced ongoing delays in introducing new nodes, and its 18A process has already witnessed some external clients withdraw after initial trial production, resulting in demand that fell short of expectations. Meanwhile, TSMC possesses the scale, ecosystem, and a broad array of loyal customers who are ready to embrace its 2nm technology, potentially complicating matters for Intel. Not only has Intel's stock performed poorly, but its annual returns have also been significantly more volatile than those of the S&P 500. The stock's returns were 6% in 2021, -47% in 2022, 95% in 2023, and -60% in 2024. In contrast, Trefis High Quality (HQ) Portfolio, which includes 30 stocks, shows much lower volatility. It has significantly outperformed the S&P 500 over the past 4 years. What accounts for this? As a collective, HQ Portfolio stocks have delivered better returns with reduced risk compared to the benchmark index; a more stable experience, as reflected in HQ Portfolio performance metrics.
Yahoo
3 hours ago
- Yahoo
BIOVAXYS ANNOUNCES AMENDED LIFE OFFERING
// NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES // VANCOUVER, BC, June 20, 2025 /CNW/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) ("BioVaxys" or the "Company") announces that it has amended the terms of its brokered private placement LIFE financing (the "Offering") previously announced on May 30, 2025, and filed an amended offering document (the "Amended Offering Document"). The Amended Offering Document updates the exercise price of the common share purchase warrant that forms part of the units ("Units") being offered by the Company from a post-consolidation exercise price of $0.60 to a post-consolidation exercise price of $0.50. As previously announced, the Company intends to consolidate the common shares of the Company (the "Common Shares") on the basis of ten (10) pre-consolidation Common Shares for one (1) post-consolidation Common Share (the "Consolidation"), and complete a concurrent Offering consisting of a minimum of 5,714,285 Units at a post-Consolidation price of $0.35 per Unit for minimum gross proceeds of $2,000,000 and a maximum of 8,571,428 Units at a post-Consolidation price of $0.35 per Unit for maximum gross proceeds of up to $3,000,000. Each Unit will consist of one (1) post-Consolidation common share in the capital of the Company (each, a "Post-Consolidation Common Share") and one (1) Post-Consolidation Common Share purchase warrant (each, a "Post-Consolidation Warrant"). Each Post-Consolidation Warrant will entitle the holder thereof to purchase one Post-Consolidation Common Share at a post-Consolidation price of $0.50 for a period of 36 months from the closing date of the Offering. Closing of the Offering is anticipated to occur on or about June 30, 2025, or such other date as the Company may agree upon provided such date is on or before July 14, 2025. Closing of the Offering is subject to the satisfaction of certain conditions, including, but not limited to, acceptance by the CSE. The Company intends to use the net proceeds raised from the Offering for research and development, general corporate purposes and working capital. Subject to compliance with applicable regulatory requirements and in accordance with National Instrument 45-106 – Prospectus Exemptions ("NI 45-106"), the Units issuable under the Offering will be offered for sale to purchasers in all provinces and territories of Canada, except Quebec, pursuant to the listed issuer financing exemption ("LIFE") under Part 5A of NI 45-106. The securities to be issued pursuant to the sale of the Units under the Offering will not be subject to resale restrictions in accordance with applicable Canadian securities laws. There is an Amended Offering Document dated June 18, 2025, related to the Offering that can be accessed under the Company's profile at and on the Company's website at Prospective investors should read this offering document before making an investment decision. This news release does not constitute an offer to sell or a solicitation of an offer to buy of any securities in the United States, or in any jurisdiction in which such offer, solicitation or sale would be unlawful. The securities described herein have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act"), or any state securities laws, and may not be offered or sold within the United States except in compliance with the registration requirements of the U.S. Securities Act and applicable state securities laws or pursuant to available exemptions therefrom. About BioVaxys Technology Corp. BioVaxys Technology Corp. ( a biopharmaceuticals company registered in British Columbia, Canada, is a clinical-stage biopharmaceutical company dedicated to improving patient lives with novel immunotherapies based on the DPX™ immune-educating technology platform and it's HapTenix© tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization for food allergy, and other immunological diseases. Through a differentiated mechanism of action, the DPX™ platform delivers instruction to the immune system to generate a specific, robust, and persistent immune response. The Company's clinical stage pipeline includes maveropepimut-S (MVP-S), based on the DPX™ platform, and in Phase IIB clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant Ovarian Cancer. MVP-S delivers antigenic peptides from survivin, a well-recognized cancer antigen commonly overexpressed in advanced cancers, and also delivers an innate immune activator and a universal CD4 T cell helper peptide. MVP-S has been well tolerated and has demonstrated defined clinical benefit in multiple cancer indications as well as the activation of a targeted and sustained, survivin-specific anti-tumor immune response. BioVaxys is also developing DPX™+SurMAGE, a dual-targeted immunotherapy combining antigenic peptides for both the survivin and MAGE-A9 cancer proteins to elicit immune responses to these two distinct cancer antigens simultaneously, DPX™-RSV for Respiratory Syncytial Virus, DPX+rPA for peanut allergy prophylaxis, and BVX-0918, a personalized immunotherapeutic vaccine using its proprietary HapTenix© 'neoantigen' tumor cell construct platform for refractive late-stage ovarian cancer. BioVaxys common shares are listed on the CSE under the stock symbol "BIOV" and trade on the Frankfurt Bourse (FRA: 5LB) and in the U.S. on the OTC Markets (OTCQB marketplace). For more information, visit and connect with us on X and LinkedIn. ON BEHALF OF THE BOARDSigned "James Passin" James Passin, Chief Executive OfficerPhone: +1 740 358 0555 Cautionary Statements on Forward Looking Information This news release includes certain "forward-looking information" and "forward-looking statements" (collectively "forward-looking statements") within the meaning of applicable securities legislation. All statements, other than statements of historical fact, included herein, without limitation, statements relating to the future operating or financial performance of the Company, are forward-looking statements. Forward-looking statements are frequently, but not always, identified by words such as "expects", "anticipates", "believes", "intends", "estimates", "potential", "possible", and similar expressions, or statements that events, conditions, or results "will", "may", "could", or "should" occur or be achieved. Forward-looking statements in this news release relate to, among other things, the proposed Consolidation, including the ratio thereof and timing thereof, and the Offering, including the size and use of proceeds, and the timing and ability of the Company to close the Offering, including obtaining approval of the Offering from the CSE. There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those expressed or implied in such forward-looking statements. Forward-looking statements reflect the beliefs, opinions and projections on the date the statements are made and are based upon a number of assumptions and estimates, primarily the assumption that BioVaxys will be successful in developing and testing vaccines, that, while considered reasonable by BioVaxys, are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies including, primarily but without limitation, the risk that BioVaxys' vaccines will not prove to be effective and/ or will not receive the required regulatory approvals. With regards to BioVaxys' business, there are a number of risks that could affect the development of its biotechnology products, including, without limitation, the need for additional capital to fund clinical trials, its lack of operating history, uncertainty about whether its products will complete the long, complex and expensive clinical trial and regulatory approval process for approval of new drugs necessary for marketing approval, uncertainty about whether its autologous cell vaccine immunotherapy can be developed to produce safe and effective products and, if so, whether its vaccine products will be commercially accepted and profitable, the expenses, delays and uncertainties and complications typically encountered by development stage biopharmaceutical businesses, financial and development obligations under license arrangements in order to protect its rights to its products and technologies, obtaining and protecting new intellectual property rights and avoiding infringement to third parties and their dependence on manufacturing by third parties. Many factors, both known and unknown, could cause actual results, performance or achievements to be materially different from the results, performance or achievements that are or may be expressed or implied by such forward-looking statements and the parties have made assumptions and estimates based on or related to many of these factors. Such factors include, without limitation, the ability of the Company to complete the Consolidation and the Offering on the terms proposed or at all, and the ability to obtain necessary approvals, including the approval of the CSE. BioVaxys does not assume any obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by applicable securities laws. The CSE has not reviewed, approved nor disapproved the contents of this news release and does not accept responsibility for the adequacy or accuracy of this news release. Logo: View original content: SOURCE BioVaxys Technology Corp. View original content: Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
3 hours ago
- Yahoo
Vancouver council approves controversial Commercial Drive rental tower project
Vancouver city council has voted to approve the rezoning of a site near the Commercial-Broadway SkyTrain station, which is set to add more than 1,000 housing units across three towers. Westbank Projects Corp. and Crombie REIT, on behalf of Snowcat Property Holdings, brought forward the proposal in 2023 to redevelop the site at 1780 East Broadway, which presently houses a Safeway supermarket and a car park. There have been proposals to redevelop the site as far back as 2019, and now that rezoning has been approved, the controversial rental towers will proceed as planned. They range in height from 36 to 43 storeys in an area that consists mostly of single-family homes, duplexes, low-rise apartments and retail buildings.A marathon public hearing saw over 100 people talk to council about the project, with critics saying the tall towers would lead to inflated property values in the area and that they would not be affordable for a majority of Vancouverites. Ultimately, however, a majority of councillors voted in favour of the project, particularly talking up an accompanying retail space — including a grocery store, office and commercial space, a city-owned child-care facility, and a public plaza running parallel to the SkyTrain station. "I don't want to see this site remain undeveloped for another 10 or 20 years," Coun. Lucy Maloney said. "I want to see a surface car park replaced with over 1,000 homes." The units will be built across the three towers. Ten per cent of them will be secured at city-wide average rental market rates and the other 90 per cent listed at prices of the developer's choosing. Maloney acknowledged that many speakers at the public hearing expressed concern about the affordability of the housing, but said "if this project fails, there will be no affordable homes at all." Coun. Sean Orr said he thought using city-wide average rents for the 10 per cent of more affordable units was flawed, given how sky-high rents are in Vancouver. "We need rental units, but I'm worried that we are giving the developer double the height and we're not seeing the full public benefits that we could be seeing at the site," he told council. Orr was the only councillor who voted against the proposal, with Coun. Pete Fry abstaining and Coun. Brian Montague absent. Application under community plan The application was considered under the Grandview-Woodland Community Plan. A referral report from city staff notes that the application "exceeds the anticipated height and density expected in the plan," but "otherwise generally meets the intent of the plan." Proponents of the plan argued that the city was in dire need of rental spaces, with one advocate even playing the accordion in city council during the public hearing to encourage councillors to vote in favour. "There's zero displacement of renters. It's mostly just a parking lot," said advocate Peter Waldkirch in a statement. However, the megatowers also faced sharp criticism. Speaking against the proposal, nurse Nancy Hay asked council to vote for rezoning applications guaranteeing at least 20 per cent below-market rental units, saying that many of her coworkers in the health-care sector could not afford to live in Vancouver due to skyrocketing rents. "I wonder if these monoliths, these proposed monolith towers, are going to house workers ... who are these workers going to be?" she asked. "They will not be my coworkers — health-care workers, lab technicians, respiratory therapists, occupational therapists, to name a few occupations ... the proposed rent, as you've heard, is way too expensive."
